Related Experiment Video
Updated: Jul 30, 2026
11:16
Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells
Published on: February 15, 2019
7.7K
CD90-targeted lentiviral vectors for HSC gene therapy
Kurt Berckmueller1, Justin Thomas1, Eman A Taha2
1Stem Cell and Gene Therapy Program, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Summary
Researchers developed novel viral vectors targeting CD90 to specifically modify rare hematopoietic stem cells (HSCs). This advancement enhances the feasibility of ex vivo gene therapy and offers potential for future in vivo applications.
Area of Science:
- Molecular Biology
- Gene Therapy
- Hematology
Background:
- Current hematopoietic stem cell (HSC) gene therapy uses CD34+ cells, containing few true HSCs, necessitating complex infrastructure.
- The CD34+CD90+ subset is crucial for engraftment, but its isolation is difficult and costly.
- A lack of HSC-specific delivery agents hinders direct modification of rare HSCs.
Purpose of the Study:
- To develop novel targeted viral vectors for specific transduction of CD90-expressing HSCs.
- To overcome limitations of current HSC gene therapy by enabling direct modification of rare HSCs.
Main Methods:
- Engineered measles- and VSV-G-pseudotyped lentiviral vectors with anti-CD90 single chain variable fragments (scFvs).
- Developed a custom hydrodynamic titration methodology for vector characterization.
- Evaluated vector performance, including capsid loading, antigen recognition, and cell fusion capabilities.
Main Results:
- Engineered vectors showed minimal impairment in functional titer and maintained cell fusion ability.
- Vectors demonstrated highly specific recognition of CD90 on cells ex vivo.
- Targeted vectors selectively transduced human HSCs with secondary colony-forming potential.
Conclusions:
- Novel HSC-targeted viral vectors were successfully developed.
- These vectors enable specific transduction of rare HSCs, enhancing ex vivo gene therapy feasibility.
- The technology holds potential for future in vivo gene therapy applications.
